Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Vertigo

ClinicalTrials.gov lists 221 trials for Vertigo or a narrower condition beneath it.

MeSH D014717 Otorhinolaryngologic Diseases C09 C10 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 14 Phase 3 Phase 3 16 Phase 4 Phase 4 14 Not applicable Not applicable 119 Observational Observational 50 Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 14 Phase 3 Phase 3 16 Phase 4 Phase 4 14 Not applicable Not applicable 119 Observational Observational 50

Trials per phase (log scale)

180 of the 221 trials are tagged with Vertigo itself; the rest are tagged with a narrower condition beneath it.

Get the Vertigo report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Vertigo trials start? (24)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 26

1998: 1 trials (Phase 2 1) 2002: 1 trials (Phase 3 1) 2005: 2 trials (Not applicable 1, Phase 4 1) 2006: 2 trials (Not applicable 1, Phase 1/2 1) 2007: 3 trials (Observational 1, Not applicable 1, Phase 4 1) 2008: 2 trials (Not applicable 1, Phase 4 1) 2009: 6 trials (Observational 1, Not applicable 3, Phase 3 2) 2010: 3 trials (Not applicable 1, Phase 4 1, Phase 1 1) 2011: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 2012: 5 trials (Not applicable 2, Phase 4 2, Phase 3 1) 2013: 11 trials (Observational 1, Not applicable 3, Phase 4 2, Phase 3 1, Phase 2 4) 2014: 10 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 2) 2015: 8 trials (Observational 1, Not applicable 5, Phase 3 1, Phase 1/2 1) 2016: 10 trials (Observational 2, Not applicable 5, Phase 4 1, Phase 3 2) 2017: 7 trials (Observational 2, Not applicable 2, Phase 2 3) 2018: 13 trials (Observational 4, Not applicable 7, Phase 3 1, Phase 1 1) 2019: 14 trials (Observational 4, Not applicable 9, Phase 2 1) 2020: 14 trials (Observational 3, Not applicable 9, Phase 2 2) 2021: 26 trials (Observational 7, Not applicable 17, Phase 4 2) 2022: 22 trials (Observational 3, Not applicable 15, Phase 3 3, Phase 1/2 1) 2023: 23 trials (Observational 7, Not applicable 13, Phase 2 1, Phase 1 2) 2024: 15 trials (Observational 3, Not applicable 9, Phase 4 2, Phase 3 1) 2025: 8 trials (Observational 2, Not applicable 4, Phase 3 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 8
2024 15
2023 23
2022 22
2021 26
2020 14
2019 14
2018 13
2017 7

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 135 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Vertigo trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 5
Phase 1/2 3
Phase 2 14
Phase 3 16
Phase 4 14
Not applicable 119
Observational 50

How many Vertigo trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 10
Recruiting 19
Enrolling by invitation 1
Active, not recruiting 8
Completed 127

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Vertigo trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Otonomy, Inc. 5
Sound Pharmaceuticals, Incorporated 5
Otolith Labs 4
Abbott 2
Apsen Farmaceutica S.A. 2

Which drugs are being tested for Vertigo? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ebselen 4
Dimenhydrinate 4
Calcium/Vitamin D 3
Betahistine 3
Meclizine 2

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Control (placebo) group 5
Dexamethasone/Dexamethasone acetate 5
Acupuncture 2
citrate of caffeine 2
Standard Care 2

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Vertigo trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Inpatient hospitalization 7 1
Infective pulmonary exacerbation of cystic fibrosis 3 1
Acute kidney injury 1 1
Ankle fracture 1 1
COVID-19 1 1

Which publications cover Vertigo? (298)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages